Danaher (NYSE:DHR)‘s stock had its “hold” rating restated by analysts at Royal Bank of Canada in a report released on Thursday. They presently have a $96.00 target price on the conglomerate’s stock. Royal Bank of Canada’s target price indicates a potential upside of 1.36% from the company’s previous close.
A number of other research firms also recently commented on DHR. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Credit Suisse Group reaffirmed a “hold” rating and set a $99.00 price target on shares of Danaher in a research report on Tuesday, December 19th. Robert W. Baird reaffirmed a “buy” rating and set a $99.00 price target on shares of Danaher in a research report on Friday, December 15th. Evercore ISI started coverage on shares of Danaher in a research report on Wednesday. They set an “outperform” rating for the company. Finally, Citigroup upped their price target on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $94.91.
Shares of Danaher (NYSE DHR) opened at $94.71 on Thursday. The company has a market capitalization of $65,880.00, a price-to-earnings ratio of 28.19, a PEG ratio of 2.04 and a beta of 1.03. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher has a twelve month low of $78.97 and a twelve month high of $95.16.
In other Danaher news, CFO Daniel L. Comas sold 88,184 shares of the company’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the completion of the transaction, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the business. GQG Partners LLC purchased a new position in Danaher in the 2nd quarter valued at about $101,000. Zions Bancorporation boosted its position in Danaher by 118.3% in the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after buying an additional 667 shares during the last quarter. Monetary Management Group Inc. boosted its position in Danaher by 10.7% in the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after buying an additional 150 shares during the last quarter. Acrospire Investment Management LLC boosted its position in Danaher by 185.5% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after buying an additional 1,100 shares during the last quarter. Finally, Motco boosted its position in Danaher by 8.8% in the 2nd quarter. Motco now owns 2,011 shares of the conglomerate’s stock valued at $170,000 after buying an additional 163 shares during the last quarter. 76.05% of the stock is owned by institutional investors.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.